Targeting of CD34+CD38-cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

Table 1 Characteristics of samples used in this study grouped by responses of cells to Tipifarnib and GO: bulk cells

AML#	Cytogenetics	FLT3 Status	NPM1 Status	CD33 MFI	Pgp status	Tip%cell loss¹	GO%cell loss¹	Tip/GO%cell loss¹	Δtox²
#19	normal	WT	WT	1.7	NEG	33	70	85	-
#1	normal	ITD	MUT	74	NEG	60	23	82	−1
#10	plus 8	ITD	WT	3.7	NEG	54	3	75	18
#17	inv(16)	ITD	WT	22	NEG	35	27	75	13
#13	normal	WT	WT		NEG	42	39	74	−7
#3	inv(16)	WT	WT	19	POS	36	0	70	34
#15	—	ITD	WT	3.3	POS	50	17	69	2
#27	complex	ITD	WT	38	NEG	0	0	68	68
#33	del(13)	ITD	—	198	NEG	38	19	65	8
#14	normal	ITD	MUT	8.7	NEG	43	4	65	18
#32	—	ITD	MUT	46	NEG	19	18	65	28
#8	normal	WT	MUT	83	NEG	20	12	63	31
#12	inv(16)	WT	WT	1.5	NEG	56	28	63	−21
#26	—	ITD	MUT		NEG	22	31	58	5
#11	—	ITD	MUT	43	NEG	11	1	55	43
#30	—	WT	WT	38	NEG	29	18	54	7
#34	normal	ITD	MUT	1.3	NEG	4	42	52	6
#20	—	WT	WT	30	POS	27	23	50	0
#21	del(5q)	ITD	MUT	59	NEG	40	25	49	−16
#5	normal	ITD	MUT	75	NEG	0	16	46	30
#25	dup1, add12, add16	WT	—	36	POS	18	10	43	15
#9	normal	ITD	MUT	8.4	NEG	19	19	42	4
#6	normal	ITD	MUT	0.19	NEG	31	37	41	−27
#16	—	—	—	51	—	21	21	40	−2
#4	—	ITD	MUT	89	NEG	33	0	35	2
#35	complex	WT	WT	18.2	POS	14	5	21	2
#31	normal	ITD	WT	11	POS	7	0	20	13
#2	—	WT	WT	3.4	POS	2	0	17	15
#7	plus 11	WT	WT	23	NEG	0	3	15	12
#29	normal	WT	MUT	140	NEG	16	0	14	−2
#28	complex	—	—	4.9	POS	0	2	2	0
#18	−5	WT	WT	2.1	POS	0	8	0	−8
#36	—	WT	WT	6.3	—	9	2	0	−11
#23	—	WT	WT	36	—	0	1	0	−1

34 AML samples used in this study ordered by magnitude of response to tipifarnib + GO (column second from the right).
¹% of cells lost after 48 hours treatment (compared to untreated control).
² Δtox = cell loss with drug combination – (cell loss with tipifarnib + cell loss with GO). No values are displayed when cell loss with tipifarnib + cell loss with GO= > 100%.

ISSN: 1471-2407